Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

11484281001

Roche

BM Blue POD Substrate, soluble

solution (ready-to-use), suitable for ELISA, pkg of 100 mL

Sinónimos:

3,3′,5,5′-Tetramethylbenzidine solution

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C16H20N2
Número de CAS:
54827-17-7
Peso molecular:
240.34
Beilstein/REAXYS Number:
2808541
MDL number:
MFCD00007748
UNSPSC Code:
12352204
PubChem Substance ID:
329749453

description

3,3′-5,5′-Tetramethylbenzidine (TMB)

Quality Level

100

form

solution (ready-to-use)

mol wt

Mr 240.35

packaging

pkg of 100 mL

manufacturer/tradename

Roche

technique(s)

ELISA: suitable

solubility

water: soluble

storage temp.

2-8°C

SMILES string

Cc1cc(cc(C)c1N)-c2cc(C)c(N)c(C)c2

InChI

1S/C16H20N2/c1-9-5-13(6-10(2)15(9)17)14-7-11(3)16(18)12(4)8-14/h5-8H,17-18H2,1-4H3

InChI key

UAIUNKRWKOVEES-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

BM Blue POD Substrate, soluble, is ideal for ELISA applications. It has been used in fluorescein-tagged exendin-4 binding assay.

Specifications

Formula: C16H20N2
Color: blue; yellow after reaction is stopped
Evaluation: photometric (450 nm)

Physical form

Solution, ready-to-use

Analysis Note

Absorption: Identical to TMB absorption spectrum

Other Notes

For life science research only. Not for use in diagnostic procedures.

Storage Class

12 - Non Combustible Liquids

wgk_germany

WGK 1

flash_point_f

No data available

flash_point_c

No data available

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Daming Zhou et al.
Nature structural & molecular biology, 27(10), 950-958 (2020-08-02)
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with
Kuan-Ying A Huang et al.
PLoS pathogens, 17(2), e1009352-e1009352 (2021-02-27)
Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral responses were detected within 3 weeks of onset of illness in all patients and the serological titre
Jiandong Huo et al.
Nature structural & molecular biology, 27(9), 846-854 (2020-07-15)
The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a more serious illness than influenza. The SARS-CoV-2 receptor binding domain (RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a prelude to
Sindhu Rajan et al.
Molecular metabolism, 4(4), 265-276 (2015-04-02)
Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diabetes therapies targeting the GLP-1 receptor (GLP-1R), expressed in numerous tissues, have diminished dose-response in patients with type 2 diabetes compared with healthy human controls. The aim of this

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico